摘要
神经胶质瘤是最常见的原发性恶性脑肿瘤,它具有普遍的致命后果。目前对神经胶质瘤患者的标准治疗是手术切除,其次是放射治疗和辅助化疗。由于治疗的耐药性和肿瘤复发,目前正在努力确定哪些分子是控制肿瘤进展的基本分子,并为神经胶质瘤患者的个体治疗提供了额外的方法。通过研究神经胶质瘤的启动和维护,研究重点是酪氨酸激酶受体的目标,包括表皮生长因子受体、PDGFR和其他重要的信号通路,如pi3k/akt和ras/raf/mapk路径。此外,最近在免疫治疗和干细胞治疗方面的进展也为神经胶质瘤治疗带来了许多策略。本文综述了各种目标治疗方法的研究进展,以提高神经胶质瘤治疗的疗效,并讨论了神经胶质瘤治疗的挑战和未来方向。
关键词: 神经胶质瘤、临床试验、靶向治疗、细胞信号转导通路、神经胶质瘤干细胞、免疫治疗。
Current Medicinal Chemistry
Title:Recent Advances in Targeted Therapy for Glioma
Volume: 24 Issue: 13
关键词: 神经胶质瘤、临床试验、靶向治疗、细胞信号转导通路、神经胶质瘤干细胞、免疫治疗。
摘要: Gliomas are the most common primary malignant brain tumors, which have a universally fatal outcome. Current standard treatment for glioma patients is surgical removal followed by radiotherapy and adjuvant chemotherapy. Due to therapeutic resistance and tumor recurrence, efforts are ongoing to identify the molecules that are fundamental to regulate the tumor progression and provide additional methods for individual treatment of glioma patients.
By studying the initiation and maintenance of glioma, studies focused on the targets of tyrosine kinase receptors including EGFR, PDGFR and other crucial signal pathways such as PI3K/AKT and RAS/RAF/MAPK pathway. Furthermore, recent advances in targeting immunotherapy and stem cell therapy also brought numerous strategies to glioma treatment. This article reviewed the researches focused on the advanced strategies of various target therapies for improving the glioma treatment efficacy, and discussed the challenges and future directions for glioma therapy.Export Options
About this article
Cite this article as:
Recent Advances in Targeted Therapy for Glioma, Current Medicinal Chemistry 2017; 24 (13) . https://dx.doi.org/10.2174/0929867323666161223150242
DOI https://dx.doi.org/10.2174/0929867323666161223150242 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Potential of Tetrandrine Against Gliomas
Anti-Cancer Agents in Medicinal Chemistry The Use of Anthracyclines for Therapy of CNS Tumors
Anti-Cancer Agents in Medicinal Chemistry Natural Product-Inspired Synthesis of Thiazolidine and Thiazolidinone Compounds and their Anticancer Activities
Current Pharmaceutical Design Near-Infrared Quantum Dot Contrast Agents for Fluorescence Tissue Imaging: A Phantom Study
Current Nanoscience Hitting a Moving Target: Glioma Stem Cells Demand New Approaches in Glioblastoma Therapy
Current Cancer Drug Targets Monitoring T Cell Responses to Cancer Immunotherapy: Can We Now Identify Biomarkers Predicting Patients Who will be Responders
Current Cancer Therapy Reviews Dietary Fatty Acids in Metabolic Syndrome, Diabetes and Cardiovascular Diseases
Current Diabetes Reviews Cancer “Stemness”- Regulating MicroRNAs: Role, Mechanisms and Therapeutic Potential
Current Drug Targets Brain Drug Delivery System: An Overview
Current Drug Therapy Targeting IGF-I, IGFBPs and IGF-I Receptor System in Cancer: The Current and Future in Breast Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Ionotropic Glutamate Receptors & CNS Disorders
CNS & Neurological Disorders - Drug Targets Microtubule Targeting Agents: A Benchmark in Cancer Therapy
Current Drug Therapy Apoptosis Induction by Ultrasound and Microbubble Mediated Drug Delivery and Gene Therapy
Current Molecular Medicine Adverse Effects and Safety of Etirinotecan Pegol, a Novel Topoisomerase Inhibitor, in Cancer Treatment: A Systematic Review
Current Cancer Therapy Reviews CIAPIN1 siRNA Inhibits Proliferation, Migration and Promotes Apoptosis of VSMCs by Regulating Bcl-2 and Bax
Current Neurovascular Research Brain Delivery of Chemotherapeutics in Brain Cancer
Anti-Cancer Agents in Medicinal Chemistry Population Pharmacokinetics of Phenytoin Based on NONMEM in Patients with Intracranial Tumor During the First Week of Post-Craniotomy
Current Drug Metabolism Neurodegeneration in the Brain Tumor Microenvironment: Glutamate in the Limelight
Current Neuropharmacology Multifunctional Mesoporous Silica Nanoparticles for Combined Therapeutic, Diagnostic and Targeted Action in Cancer Treatment
Current Drug Targets Human Microdialysis
Current Pharmaceutical Biotechnology